FDA Grants Priority Review to Atezolizumab in NSCLC

Share this content:
The FDA has granted Priority Review for atezolizumab for the treatment of locally advanced or metastatic non-small cell lung cancer.
The FDA has granted Priority Review for atezolizumab for the treatment of locally advanced or metastatic non-small cell lung cancer.

The U.S. Food and Drug Administration (FDA) has granted Priority Review for atezolizumab for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express programmed death ligand-1 (PD-L1) and who have progressed on or after a platinum-containing regimen.1

Priority Review designation was based upon results from the phase 2 BIRCH trial, which demonstrated an objective response rate of 27% (P = .0001) among patients whose disease progressed on prior treatments and also expressed the highest levels of PD-L1. Median overall survival has not yet been reached.

The BIRCH study is a multicenter, open-label, single-arm phase 2 trial that evaluated the safety and efficacy of the immunotherapy in 667 patients with locally advanced or metastatic NSCLC whose disease expressed PD-L1. All participants received atezolizumab 1200 mg intravenously every 3 weeks.

In terms of safety, 11% of patients in the BIRCH study experienced grade 3 or 4 treatment-related adverse events. The most frequently reported adverse events were fatigue, diarrhea, nausea, pruritus, pyrexia, decreased appetite, asthenia, rash, and arthralgia.

The anti-PD-L1 monoclonal antibody was also assessed in the phase 2 POPLAR trial, which compared the safety and efficacy of atezolizumab with that of docetaxel in patients with previously treated NSCLC. Findings showed that atezolizumab significantly improved overall survival compared with docetaxel.

RELATED: Crizotinib Effective for NSCLC Brain Metastases

The FDA will decide whether to approve atezolizumab for patients with NSCLC whose tumors express PD-L1 by October 19, 2016.

Atezolizumab is also being studied in renal cell carcinoma, breast cancer, melanoma, and bladder cancer.

Reference

  1. FDA grants priority review for Genentech's cancer immunotherapy atezolizumab in specific type of lung cancer [news release]. South San Francisco, CA: Genentech; April 10, 2016. http://www.gene.com/media/press-releases/14622/2016-04-10/fda-grants-priority-review-for-genentech. Accessed April 11, 2016.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters